Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Innovation Council To Examine Pharmacogenomic Product Coverage

Executive Summary

The Centers for Medicare & Medicaid Services' Council for Technology & Innovation will consider coverage of pharmacogenomic products

You may also be interested in...



CMS Developing Guidance On Coverage Decisions For Clinical Trials

The Centers for Medicare & Medicaid Services will produce a guidance document on Medicare coverage of products used in clinical trials or registries

CMS Developing Guidance On Coverage Decisions For Clinical Trials

The Centers for Medicare & Medicaid Services will produce a guidance document on Medicare coverage of products used in clinical trials or registries

Medicare Drug Coding Drops Six-Month Marketing Requirement

Pharmaceutical manufacturers will no longer need to submit six months of marketing data for a drug when seeking a Medicare reimbursement code

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel